Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Biopsy Gleason pattern 4 burden refines preoperative risk stratification in prostate cancer.
Journal: Urologic oncology
Published: March 06, 2026
Not all PI-RADS 3 lesions are the same: Higher rate of clinically significant prostate cancer among Black men on targeted biopsy in a diverse cohort.
Journal: Urologic oncology
Published: August 07, 2025
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study.
Journal: Clinical genitourinary cancer
Published: April 23, 2025
Because Doing "It" Matters to Patients: Development and Evaluation of a What Matters to Me Tool That Elicits Patients' Priorities to Support Cancer Treatment Shared Decision-Making.
Journal: Cancer medicine
Published: February 06, 2025
Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel.
Journal: The Journal of urology
Published: November 19, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
Journal: The Journal of urology
Published: May 05, 2024
Performance of cognitive vs. image-guided fusion biopsy for detection of overall and clinically significant prostate cancer in a multiethnic population.
Journal: Urologic oncology
Published: August 16, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency.
Journal: Urologic oncology
Published: July 25, 2023
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023.
Journal: Journal for immunotherapy of cancer
Published: January 24, 2023
The Development of Non-Invasive Diagnostic Tools in Bladder Cancer.
Journal: OncoTargets and therapy
Published: December 22, 2021
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
Journal: The Journal of urology
Published: August 26, 2021
Last Updated: 09/26/2026